<?xml version="1.0" encoding="UTF-8"?>
<p>A 24-year-old, Chinese HIV-infected patient with a 2-year treatment history with tenofovir, lamivudine and efavirenz (CD4 cell count and HIV-RNA levels unreported), had a non-severe course of COVID-19 (
 <xref rid="B11" ref-type="bibr">11</xref>). Lopinavir/ritonavir had been added to the antiretroviral regimen after COVID-19 diagnosis (
 <xref rid="B11" ref-type="bibr">11</xref>).
</p>
